Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03566199 · ClinicalTrials.gov registry record · Phase 1
MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
A Phase 1 study, sponsored by Sabine Mueller, MD, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03566199: Completed Phase 1 study, sponsored by Sabine Mueller, MD, PhD.
NCT03566199 is a Phase 1 study that has completed, run by Sabine Mueller, MD, PhD. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03566199, a Phase 1 study, has completed, sponsored by Sabine Mueller, MD, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Adverse events and clinically significant laboratory abnormalities which meet Grade 3, 4, or 5 criteria according to Common Terminology Criteria for Adverse Events (CTCAE) classified by investigators and treating physicians as related to study treatment (probable, possible, and definite) will be summarized by maximum intensity/grade. Adverse events will be graded according to CTCAE version 4.0.
Interventions
- DRUG Panobinostat Nanoparticle Formulation MTX110
- DRUG Convection-Enhanced Delivery (CED)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
What the finished NCT03566199 record still lists
NCT03566199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Panobinostat Nanoparticle Formulation MTX110 is the first listed.
NCT03566199 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03566199 about?
NCT03566199 is a clinical study titled "MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma". This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by blocking some of the enzymes need...
What is the current status of trial NCT03566199?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2018-05-22. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03566199?
The interventions under investigation include: Panobinostat Nanoparticle Formulation MTX110 (DRUG), Convection-Enhanced Delivery (CED) (DRUG).
Who is sponsoring clinical trial NCT03566199?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03566199's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI